Igantet (Human Tetanus Immunoglobulin)

Igantet, a human tetanus immunoglobulin, provides passive immunity against tetanus toxin.

• Pre‑exposure prophylaxis in individuals with uncertain vaccination status: provides immediate protection pending active immunization.
• Post‑exposure prophylaxis after contaminated wound: neutralizes toxin to prevent tetanus development.
• Adjunctive therapy in confirmed tetanus cases: supplies antibodies while active vaccine induces long‑term immunity.

• Human Tetanus Immunoglobulin in Igantet supplies exogenous anti‑tetanus antibodies that bind to circulating tetanus toxin, preventing its attachment to neuronal membranes and neutralizing its neurotoxic effects. This passive immunization offers immediate protection while the patient's own immune response to active vaccination develops over time.

Igantet may be associated with adverse reactions typical of human immunoglobulin preparations.

Common Side Effects

• Pain at the injection site: mild to moderate discomfort.
• Redness or swelling at the injection site: localized inflammatory response.
• Fever: transient elevation of body temperature.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Serum sickness-like reaction: fever, rash, arthralgia occurring days after administration.
• Severe hypotension: sudden drop in blood pressure during or after injection.
• Urticaria: widespread hives indicating allergic response.
• Hemolysis: destruction of red blood cells in rare cases.

When using Igantet, clinicians should observe the following precautions to ensure safe administration.

• Assess vaccination history: verify prior tetanus immunization status before administration.
• Screen for hypersensitivity: avoid in patients with known allergy to human immunoglobulins.
• Monitor during injection: observe for immediate allergic reactions such as rash or breathing difficulty.
• Use aseptic technique: prepare injection site with sterile equipment to prevent infection.
• Avoid in IgA‑deficient patients with anti‑IgA antibodies: risk of severe anaphylaxis.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igantet can interact with certain medicines and biologics; awareness of these interactions helps manage patient safety.

Major Interactions (Avoid)

• Concurrent administration of other human immunoglobulins: may cause immunoglobulin overload and increased viscosity.
• Live attenuated vaccines within 3 months: reduced vaccine efficacy due to passive antibodies.
• Simultaneous blood product transfusion: may interfere with antibody activity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): increased risk of bleeding at injection site.
• Immunosuppressive agents (e.g., corticosteroids): may diminish the protective effect of administered antibodies.
• Active tetanus vaccine given shortly after Igantet: schedule appropriately to avoid interference.